Press release: New Phase 3 data presented at WORLDSymposium™ reinforce Nexviazyme® (avalglucosidase alfa) as potential new standard of care for all people living with late-onset Pompe disease
Retrieved on:
Friday, February 24, 2023
Periodic breathing, Splenic infarction, Vital capacity, Glycogen storage disease type II, Safety, Patient, Coordinated Specialty Care, COMET, Cancer, IOPD, Hives, Alglucosidase alfa, Aes, New York Genome Center, Medical genetics, Walking, FVC, Duke University Hospital, YT, Glycogen, Erythema, Pharmaceutical industry, Nursing, Surveying, Pediatrics, Avalglucosidase alfa
Additionally, a separate analysis of respiratory function showed clinical benefit over two years for patients who switched to Nexviazyme regardless of prior response to alglucosidase alfa.
Key Points:
- Additionally, a separate analysis of respiratory function showed clinical benefit over two years for patients who switched to Nexviazyme regardless of prior response to alglucosidase alfa.
- It is also approved for infantile-onset Pompe disease (IOPD) in certain markets outside of the US.
- No new safety signals were observed in patients who switched from alglucosidase alfa to Nexviazyme during the extension period.
- Subgroup analyses were also performed to assess respiratory function outcomes for the 44 patients who switched to Nexviazyme in the long-term extension period of the Phase 3 COMET study.